Breast implant-associated anaplastic large cell lymphoma - From diagnosis to treatment

Show full item record



Permalink

http://hdl.handle.net/10138/297933

Citation

Kaartinen , I , Sunela , K , Alanko , J , Hukkinen , K , Karjalainen-Lindsberg , M -L & Svarvar , C 2017 , ' Breast implant-associated anaplastic large cell lymphoma - From diagnosis to treatment ' , European Journal of Surgical Oncology , vol. 43 , no. 8 , pp. 1385-1392 . https://doi.org/10.1016/j.ejso.2017.05.021

Title: Breast implant-associated anaplastic large cell lymphoma - From diagnosis to treatment
Author: Kaartinen, I.; Sunela, K.; Alanko, J.; Hukkinen, K.; Karjalainen-Lindsberg, M. -L.; Svarvar, C.
Contributor: University of Helsinki, Department of Diagnostics and Therapeutics
University of Helsinki, Medicum
University of Helsinki, II kirurgian klinikka
Date: 2017-08
Language: eng
Number of pages: 8
Belongs to series: European Journal of Surgical Oncology
ISSN: 0748-7983
URI: http://hdl.handle.net/10138/297933
Abstract: Breast lymphomas comprise a rare group of malignant breast tumors. Among these, a new entity has emerged as a potentially under diagnosed disease. Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) most often manifests as a late periprosthetic effusion between 1 and 10 years after the implantation of silicone or saline-filled breast prostheses. BI-ALCL is an anaplastic lymphoma kinase-negative T-cell lymphoma that has a distinctively different clinical course than other breast lymphomas or ALCLs. Diagnosis is based on aspiration of the effusion around the implant and CD30 positivity of the sample. Every periprosthetic effusion after breast augmentation or reconstruction using implants should be considered as potential BI-ALCL until proven otherwise. The majority of cases at diagnosis are in the in situ stage, i.e., confined to the lumen around the prosthesis. Most patients have an excellent prognosis when complete removal of the capsule and prosthesis with negative margins is achieved surgically. Some patients, however, develop infiltrative disease with a potentially life-threatening clinical course. Treatment planning regarding the extent of surgery and role of adjuvant therapy, especially in advanced cases, requires further investigation. (c) 2017 Elsevier Ltd, BASO-The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Subject: ALCL
BI-ALCL
ALK-negative lymphoma
Breast implants
Seroma
Cytotoxic c-cell
OF-THE-LITERATURE
SILICONE IMPLANTS
BIOFILM INFECTION
SEZARY-SYNDROME
PATIENT
INVOLVEMENT
CAPSULE
WOMEN
3126 Surgery, anesthesiology, intensive care, radiology
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0748798317305334_main.pdf 1.136Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record